Literature DB >> 18176802

Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy.

Elisabetta Poluzzi1, Petar Strahinja, Monica Lanzoni, Antonio Vargiu, Maria Chiara Silvani, Domenico Motola, Antonio Gaddi, Alberto Vaccheri, Nicola Montanaro.   

Abstract

AIM: To evaluate the pattern of use of statins in the Emilia Romagna Region, with a focus on the therapeutic regimens and the patient's risk profile as predictors of adherence to therapy.
METHODS: All patients from Emilia Romagna (4,027,275 inhabitants) receiving statin prescriptions in January-February 2005 were selected and observed for 12 months in terms of their statin regimen and use of other drugs for cardiovascular risk prevention. Previous hospital admissions for major cardiovascular events were also obtained. Adherence to statins was evaluated in terms of coverage (covered: >or=300 tablets/year). The relationship between coverage and risk profile (age, sex, other cardiovascular drugs, previous cardiovascular events and choice of drugs/dosages) was analysed by multivariate logistic regression.
RESULTS: Among the 137,217 patients receiving at least one prescription in the observation period, the rate of coverage was 46%. Coverage was statistically higher in patients with a previous hospital admission (secondary prevention) [Odds ratio (OR) 1.19; 95% confidence interval (95% CI) 1.16, 1.22], in those concomitantly treated with three to four different cardiovascular drugs (OR 2.77; 95% CI 2.66, 2.89). The coverage was also statistically higher in patients aged 50-69 years (OR 1.14; 95% CI 1.08, 1.20) and among males (OR 1.21; 95% CI 1.18, 1.23).
CONCLUSIONS: Less than half of patients receiving statin therapy took their medication daily, with a coverage only slightly higher in patients at higher cardiovascular risk. Three-quarters of the patients received statin therapy in primary prevention, whereas the benefits of statins are documented mostly for patients in secondary prevention. These findings strengthen the need to sensitise physicians and patients to the correct use of statins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18176802     DOI: 10.1007/s00228-007-0428-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization.

Authors:  Robert J Valuck; Setareh A Williams; Marilyn MacArthur; Joseph J Saseen; Kavita V Nair; Marianne McCollum; Joe E Ensor
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

2.  Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study.

Authors:  W B KANNEL; T R DAWBER; A KAGAN; N REVOTSKIE; J STOKES
Journal:  Ann Intern Med       Date:  1961-07       Impact factor: 25.391

3.  Statins down under.

Authors:  Andrea Mant; Jocelyn Lowinger; Wayne Hall; Susan Whicker; Clare Ringland; Helen Stark
Journal:  Br J Clin Pharmacol       Date:  2006-08-02       Impact factor: 4.335

4.  Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use.

Authors:  M Alan Brookhart; Amanda R Patrick; Sebastian Schneeweiss; Jerry Avorn; Colin Dormuth; William Shrank; Boris L G van Wijk; Suzanne M Cadarette; Claire F Canning; Daniel H Solomon
Journal:  Arch Intern Med       Date:  2007-04-23

5.  Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data.

Authors:  J J Caro; J L Speckman; M Salas; G Raggio; J D Jackson
Journal:  CMAJ       Date:  1999-01-12       Impact factor: 8.262

6.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

Authors:  J C LaRosa; J He; S Vupputuri
Journal:  JAMA       Date:  1999 Dec 22-29       Impact factor: 56.272

7.  American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively.

Authors:  P McElduff; M Jaefarnezhad; P N Durrington
Journal:  Heart       Date:  2006-05-22       Impact factor: 5.994

8.  High persistence of statin use in a Danish population: compliance study 1993-1998.

Authors:  John Larsen; Morten Andersen; Jakob Kragstrup; Lars F Gram
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

9.  Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage.

Authors:  Elisabetta Poluzzi; Petar Strahinja; Alberto Vaccheri; Antonio Vargiu; Maria Chiara Silvani; Domenico Motola; Giulio Marchesini; Fabrizio De Ponti; Nicola Montanaro
Journal:  Br J Clin Pharmacol       Date:  2006-11-10       Impact factor: 4.335

10.  [The global cardiovascular risk chart].

Authors:  Simona Giampaoli; Luigi Palmieri; Paolo Chiodini; Giancarlo Cesana; Marco Ferrario; Salvatore Panico; Lorenza Pilotto; Roberto Sega; Diego Vanuzzo
Journal:  Ital Heart J Suppl       Date:  2004-03
View more
  12 in total

1.  Statins for children? A word of caution.

Authors:  Zemira Cannioto; Giorgio Tamburlini; Federico Marchetti
Journal:  Eur J Clin Pharmacol       Date:  2008-11-06       Impact factor: 2.953

2.  Mitophagy protects against statin-mediated skeletal muscle toxicity.

Authors:  Mridula Ramesh; Juliane C Campos; Pamela Lee; Yang Song; Genaro Hernandez; Jon Sin; Kyle C Tucker; Hannaneh Saadaeijahromi; Michael Gurney; Julio C B Ferreira; Allen M Andres
Journal:  FASEB J       Date:  2019-08-23       Impact factor: 5.191

3.  Medication adherence: WHO cares?

Authors:  Marie T Brown; Jennifer K Bussell
Journal:  Mayo Clin Proc       Date:  2011-03-09       Impact factor: 7.616

4.  Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study.

Authors:  Elisabetta Poluzzi; Carlo Piccinni; Paolo Carta; Aurora Puccini; Monica Lanzoni; Domenico Motola; Alberto Vaccheri; Fabrizio De Ponti; Nicola Montanaro
Journal:  Eur J Clin Pharmacol       Date:  2010-12-09       Impact factor: 2.953

5.  Adherence to preventive statin therapy according to socioeconomic position.

Authors:  Helle Wallach-Kildemoes; Morten Andersen; Finn Diderichsen; Theis Lange
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

6.  Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment.

Authors:  Gregory S Calip; Denise M Boudreau; Elizabeth T Loggers
Journal:  Breast Cancer Res Treat       Date:  2013-01-29       Impact factor: 4.872

7.  Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study.

Authors:  Philippe Latry; Mathieu Molimard; Bernard Dedieu; Thierry Couffinhal; Bernard Bégaud; Karin Martin-Latry
Journal:  BMC Cardiovasc Disord       Date:  2011-07-26       Impact factor: 2.298

8.  Reasons for (non)compliance with intervention following identification of 'high-risk' status in the NHS Health Check programme.

Authors:  R J McNaughton; J Shucksmith
Journal:  J Public Health (Oxf)       Date:  2014-09-18       Impact factor: 2.341

9.  Trends in total and low-density lipoprotein cholesterol among U.S. adults: contributions of changes in dietary fat intake and use of cholesterol-lowering medications.

Authors:  Earl S Ford; Simon Capewell
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

10.  Evaluating an implementation strategy in cardiovascular prevention to improve prescribing of statins in Germany: an intention to treat analysis.

Authors:  Heidemarie Keller; Oliver Hirsch; Petra Kaufmann-Kolle; Tanja Krones; Annette Becker; Andreas C Sönnichsen; Erika Baum; Norbert Donner-Banzhoff
Journal:  BMC Public Health       Date:  2013-07-02       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.